Comparative Immunogenicity Study of Multiple Doses of Proposed Pegfilgrastim Biosimilar, INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.

NCT04015232 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunogenicity
Healthy Volunteers

Interventions

COMBINATION_PRODUCT: INTP5
COMBINATION_PRODUCT: US Neulasta

Sponsor

Intas Pharmaceuticals, Ltd.

Collaborators

[object Object]